肿瘤预防与治疗2017，Vol.30Issue(4)：281-284,4.DOI:10.3969/j.issn.1674-0904.2017.04.008
长短效重组人粒细胞刺激因子治疗Ⅳ度骨髓抑制的疗效评价和成本效果分析
The Efficacy Evaluation and Cost-Effectiveness Analysis for Long and Short-Effective Recombinant Human Granulocyte Stimulator for Bone Marrow Suppression
程幼夫 1余微 1王怡鑫 2周进 3李晓霞1
作者信息
- 1. 610041 成都,四川省肿瘤医院 健康管理中心
- 2. 610041 成都,四川省肿瘤医院 临床药学管理部
- 3. 610041 成都,四川省肿瘤医院 胸部肿瘤内科
- 折叠
摘要
Abstract
Objective:To evaluate the efficacy and cost-effectiveness of myelosuppression treated by long and short-acting recombinant human granulocyte-stimulating factors,aiming at using the medicine with safty,effectiveness and economically.Methods:A retrospective analysis was conducted for 104 patients with Ⅳ degree of myelosupportression as a result of primary chemotherapy between January 2015 and June 2016.Patients were divided into two groups.54 of them (Group A) used the recombinant human granulocyte colony-stimulating factor intravenous drip regimen,and 50 of them (group B) used polyethylene glycol recombinant human granulocyte stimulator subcutaneous injection regimen.The short-effective curative effect and adverse reaction evaluation were compared after treating for 3 days.At the same time,the treatment cost and cost-effectiveness between the two groups was compared.Results:It showd that the average costs of the two groups were RMB 1222.5 for group A and RMB 3574 for group B..The cure rates of leukopenia reduction were 38.9％ and 34.0％,the overall cure rates were 77.8％ and 82.0％,respectively.No significant difference between the two groups (P ＞ 0.05) were found.The incidences of adverse reactions were 31.5％ and 14.0％ respectively and showd significant difference.From cost-effectiveness perspective,group A was more economical.Conclusion:Considering the effectiveness and economic usages of medicine,group A regimen has advantage for severe myelosuppression treatment,while Group B is more secure and is more suitable for daytime chemotherapy.关键词
有效性评价/药物经济学评价/成本效果分析/骨髓抑制Key words
Effectiveness/Pharmacoeconomics/Cost-effectiveness analysis/Myelosuppression分类
医药卫生引用本文复制引用
程幼夫,余微,王怡鑫,周进,李晓霞..长短效重组人粒细胞刺激因子治疗Ⅳ度骨髓抑制的疗效评价和成本效果分析[J].肿瘤预防与治疗,2017,30(4):281-284,4.
